DSIP for sleep: evidence regarding insomnia, sleep quality, and sleep deprivation

Delta sleep-inducing peptide (DSIP) has shown some sleep-related effects in small, mostly older human studies, but available data do not support its efficacy or approved use in the treatment of insomnia, reduced sleep quality, or the effects of sleep deprivation.

DSIP is often described on the internet as a „sleep peptide,” yet the name itself suggests a level of certainty that the scientific literature does not support. In a few studies conducted mainly from the late 1970s to the early 1990s, changes related to sleep onset latency, sleep efficiency, nocturnal awakenings, or deep NREM sleep were observed. In contrast, other controlled studies showed effects that were minor, statistically uncertain, or of limited clinical significance. Animal study results were also inconsistent: depending on the species, route of administration, timing of administration, and the studied form of the molecule, DSIP increased deep slow-wave sleep, caused minimal changes, or even reduced sleep.

Therefore, the practical interpretation of these data should remain cautious. DSIP is an experimental nonapeptide with a not fully elucidated physiological role and mechanism of action, rather than an established sleep medication. It should not be treated as an equivalent to melatonin, approved medications used for insomnia, or cognitive behavioral therapy for insomnia (CBT-I). Designations such as „DSIP 5 mg” only indicate the declared amount of material in the vial; they do not imply a clinically validated human dose, nor do they confirm that the product has been tested for the treatment of insomnia.

What is delta sleep-inducing peptide?

Delta sleep-inducing peptide is a nine-amino-acid peptide, also known by the international name emideltide, with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was identified during experiments in which venous blood collected from the cerebral vessels of sleeping rabbits appeared to promote sleep-related electroencephalographic activity in other rabbits. In basic animal studies, synthetic DSIP administered directly into the brain increased EEG features associated with spindle and delta activity, which contributed to the hypothesis that DSIP may act as an endogenous sleep-promoting substance [1].

However, this early observation did not confirm the physiological role of DSIP in humans. Later reviews emphasized that researchers failed to identify a unique gene encoding DSIP, a typical peptide precursor, or a specific DSIP receptor. Measurements referred to as „DSIP-like immunoreactivity” may detect DSIP that is part of larger molecules or chemically similar material, rather than freely circulating, unmodified DSIP. Its natural concentrations, secretion pattern, metabolism, and physiological function therefore remain uncertain [2,3]. Describing DSIP as a sleep-inducing peptide reflects the circumstances of its discovery, but does not mean that modern clinical research has confirmed it as a natural human sleep hormone.

Sleep itself encompasses several distinct physiological states. Polysomnography combines an EEG recording with the recording of eye movements and muscle tone to distinguish NREM sleep from REM sleep. Modern classification divides NREM sleep into phases N1, N2, and N3, with N3 corresponding to slow-wave, or deep, sleep. Older DSIP studies used terms such as phase 1, phase 2, phases 3 and 4, „deep slow-wave sleep,” or „paradoxical sleep”; paradoxical sleep essentially corresponds to the REM phase, while the former phases 3 and 4 are now combined as N3. Terminological differences matter because an increase in delta wave activity in the EEG does not necessarily imply a longer total sleep time, faster sleep onset, or better functioning the next day.

Does DSIP help with falling asleep and sleep?

DSIP may affect certain sleep parameters under experimental conditions, but data from human studies are too limited, old, and inconsistent to conclude that the peptide reliably improves sleep.

Some of the most favorable results came from small studies by Schneider-Helmert and colleagues. In one double-blind crossover study involving just six healthy volunteers, slow intravenous administration of DSIP in the morning was associated with greater sleep pressure and longer sleep during a daytime nap opportunity; a subsequent nighttime recording showed shorter sleep latency, less stage 1 sleep, and greater sleep efficiency [4]. In another experiment involving six middle-aged individuals with chronic insomnia, DSIP was associated with longer, less fragmented sleep and a slight increase in REM sleep, with the most noticeable sleep-promoting effect appearing only in the second hour [5]. These observations suggest a possible delayed regulatory action rather than the rapid and predictable sedation typical of classic hypnotic drugs.

Several subsequent publications by the same or a related research group described improvement following repeated intravenous administration of DSIP in small groups of individuals with chronic insomnia [6–9]. However, these publications should not be interpreted as a series of large, independent replications. They originated from a limited research network, involved small sample sizes, and some summarized overlapping experiments or observations without a control group. One open-label study included seven patients, six of whom were reported to have prolonged improvement, but without a blinded placebo group, it was impossible to distinguish the effect of DSIP from participant expectations, regression to the mean, changes in sleep schedule, or the naturally variable course of insomnia [7].

Independent controlled studies yielded significantly less convincing results. In a double-blind crossover study, Monti and colleagues observed a numerical decrease in the number of awakenings, sleep onset latency for NREM sleep, total wake time, and wake after sleep onset, but these differences were not statistically significant compared to baseline or placebo. Total sleep time and NREM sleep time increased mainly due to the lengthening of stage 2 rather than deep slow-wave sleep, while stages 3 and 4 as well as REM remained essentially unchanged. The authors concluded that the observed changes were of little clinical significance [10]. In a later double-blind parallel study involving 16 people with chronic insomnia, DSIP seemingly improved sleep efficiency and shortened sleep latency, but the effect was weak and partly resulted from a chance variation in the placebo group. Participants did not report an improvement in subjective sleep quality, and the authors concluded that a significant therapeutic benefit was unlikely [11].

Altogether, these results represent a historically and mechanistically interesting signal, but they do not provide reliable evidence of effective treatment. No large, contemporary, multicenter randomized trial has been conducted to demonstrate significant improvement in insomnia severity, daytime functioning, relapse rates, or long-term quality of life.

Does DSIP cause drowsiness or make it easier to fall asleep?

DSIP has not been shown to cause immediate drowsiness, and small human studies suggest that any sleep-related effects may be delayed, irregular, and different from those of typical sedatives.

In a crossover study involving six volunteers, the researchers described increased sleep pressure, but not the typical pattern of a sedative effect [4]. In a study involving six individuals with insomnia, even mild stimulation was observed in the first hour after administration, whereas more favorable changes appeared mainly in the second hour [5]. A later summary by the same research group suggested an onset of action after about an hour and the persistence of the effect beyond the administration period itself, but this interpretation was based on several very small, related studies rather than a definitive pharmacodynamic study [6].

Sleep onset time is just one element of sleep. A person may fall asleep faster while simultaneously spending more time awake later in the night, not get any additional deep sleep, or not feel better the next day. On the other hand, a given intervention may alter EEG activity or the proportions of individual sleep phases without inducing noticeable sleepiness. Available DSIP studies have not shown a consistent relationship between objective polysomnography results and the subjective sense of being rested, daytime alertness, or improved functioning. For this reason, claims that DSIP simply puts people to sleep go beyond what has actually been demonstrated in research.

There is also no evidence-based way to convert a product label, such as „DSIP (delta sleep-inducing peptide) – 5 mg,” into an expected sleep onset time. Historical human studies typically utilized controlled intravenous administration, with exposure determined relative to body weight or in molar units rather than based on the commercial potency of the vial. Purity, molecular identity, formulation, route of administration, and pharmacokinetics can affect exposure. The amount stated on the vial is not a clinical treatment protocol, and available studies do not support the standalone use of DSIP for sleep improvement.

DSIP and sleep architecture

In some experiments, DSIP increased activity characteristic of deep slow-wave sleep, but it has not been shown to consistently improve overall sleep architecture in humans.

Sleep architecture refers to the progression and proportions of NREM and REM sleep stages throughout the night, including the cyclical transitions between lighter N1/N2 sleep, deep N3 sleep, and the REM phase. A clinically useful intervention should primarily improve a specific problem, such as long sleep onset latency or excessive wakefulness after sleep onset, without causing harmful next-day effects and without disrupting the restorative sleep phases. Therefore, greater delta wave activity does not automatically mean better sleep.

Human studies do not show a consistent pattern of changes across individual phases. An early experiment involving six insomnia patients showed fewer sleep interruptions and a slight increase in the REM phase, but the sample was very small [5]. Monti and colleagues reported an increase in NREM sleep mainly due to the elongation of phase 2, while slow-wave phases 3 and 4 as well as REM remained practically unchanged [10]. A double-blind study involving 16 participants showed only minor objective changes with no corresponding improvement in perceived sleep quality [11]. The inconsistency of these results makes it impossible to reliably state that native DSIP increases the N3 phase, REM phase, or a specific, beneficial restorative sleep profile in humans.

Animal studies additionally show why simple conclusions are unjustified. In one study involving ten cats, administering DSIP into the brain increased total and deep slow-wave sleep and shortened sleep latency [12]. Subcutaneous administration in eight cats increased deep slow-wave sleep and EEG delta activity, but did not significantly affect total waking time, total slow-wave sleep time, sleep latency, or REM phase duration [13]. In contrast, in another study, intraperitoneal administration of DSIP reduced sleep, especially light slow-wave sleep and REM, while prolonging the latency to REM onset [14]. These results come from different experimental conditions and demonstrate biological variability rather than a confirmed sleep effect in humans.

Research on phosphorylated DSIP further complicates the picture. The phosphorylated analogue increased slow-wave and paradoxical/REM sleep in rats, and another study in rats showed an increase in both types of sleep during long-term infusion into the brain [15,16]. However, phospho-DSIP is a chemically different molecule than native DSIP. The results concerning this analogue cannot be treated as evidence that regular DSIP produces the same effect in humans, at the same time, and to the same extent.

Evidence table: what DSIP sleep studies really show

DSIP for insomnia: what did clinical trials show?

Clinical studies on DSIP in insomnia were small and yielded contradictory results, and better-controlled trials have not shown a clear or clinically significant benefit.

Chronic insomnia is more than just a single poorly slept night. It is characterized by persistent difficulties in falling asleep, staying asleep, or obtaining restorative sleep, accompanied by daytime consequences. Modern clinical trials typically utilize well-defined diagnostic criteria, adequate randomization, pre-defined endpoints, validated insomnia questionnaires, polysomnography or actigraphy where warranted, systematic monitoring of adverse events, and adequately large sample sizes to distinguish a true treatment effect from the natural night-to-night variability of sleep. Most DSIP studies were conducted before many of these standards became routine.

More favorable studies included acute experiments involving six patients, small series with repeated administration, a placebo-controlled study with 14 subjects, and a study involving 18 subjects describing the normalization of some sleep parameters after a short cycle [5–9]. These publications are significant because they represent actual human studies rather than merely extrapolating from animal experiments. However, they still do not determine whether DSIP induces reproducible, clinically meaningful improvement. Small trials increase the risk of accidental findings, selective reporting becomes more problematic when analyzing multiple sleep phases and time intervals, and the short follow-up period makes it difficult to assess the durability of the effect and side effects.

Particularly important are negative or inconclusive controlled trials. Monti and colleagues failed to demonstrate a significant, placebo-adjusted improvement in primary sleep continuity parameters, nor an increase in slow-wave sleep or REM [10]. Bes and colleagues also found no improvement in subjective sleep quality and concluded that a significant therapeutic benefit was unlikely [11]. Although both studies were small by modern standards, together they weaken the claim that clinical trials consistently confirm the efficacy of DSIP in the treatment of insomnia.

There is also no extensive Phase 2 or Phase 3 research program determining the dose-response relationship, optimal formulation, risk of interactions, withdrawal effects, or comparative efficacy. Referring to historical publications as „DSIP clinical trials” is broadly correct, but it should not imply the scale or regulatory rigor characteristic of modern insomnia drug development. No published data supports DSIP as a substitute for CBT-I or as an approved medication tailored to the diagnosis and risk profile of a specific patient.

DSIP and Sleep Quality

DSIP has not shown a consistent improvement in sleep quality, particularly when quality was assessed by the individual themselves rather than solely based on EEG or other laboratory measurements.

Objective and subjective sleep parameters are related, but they are not the same. Polysomnography can measure sleep onset latency, total sleep time, wake after sleep onset, sleep efficiency, stage distribution, awakenings, and EEG activity. Subjective outcomes, on the other hand, assess whether sleep felt restorative, whether awakenings were troublesome, and whether daytime energy, concentration, mood, or functioning improved. Treatment can alter a laboratory parameter without simultaneously providing a perceptible benefit to the patient.

Such discrepancies are evident in the literature on DSIP. Some early studies reported objectively longer or less fragmented sleep [4,5], whereas a controlled study involving 16 participants showed no improvement in subjective sleep quality despite seemingly beneficial changes in sleep efficiency and sleep onset latency [11]. The literature also lacks contemporary, validated endpoints, such as changes in the Insomnia Severity Index, the patient’s global assessment of improvement, sustained improvement in daytime functioning, or clinically defined remission.

Claims that DSIP provides „restorative” or „higher-quality” sleep should therefore be treated as hypotheses rather than proven benefits. Increased delta activity in an animal’s EEG does not mean that a person will wake up feeling more rested. Similarly, a slight change observed during a single night in a laboratory setting does not prove better sleep at home, where sleep quality is influenced by factors such as stress, light, work hours, stimulants, breathing disorders, restless legs syndrome, pain, and mental health issues.

DSIP in sleep deprivation research

Studies on sleep deprivation have not shown that DSIP reliably replaces lost sleep, prevents a decline in functioning, or accelerates recovery in humans.

In one experiment with cats, DSIP was evaluated after 72 hours of selective paradoxical/REM sleep deprivation. Administration into the brain did not significantly change the total slow-wave sleep time, REM sleep, total sleep time, or sleep onset latency. However, it decreased wakefulness and light slow-wave sleep while increasing the proportion of the deeper stage of slow-wave sleep [17]. This result corresponds more to a redistribution of restorative sleep phases than to a true replenishment of lost REM sleep. Because the study was performed on animals and used direct administration into the brain, it cannot serve as evidence of efficacy in sleep deprivation in humans.

In a small observational study involving seven healthy men, plasma levels of DSIP-like immunoreactivity were measured during normal nighttime sleep, partial nighttime sleep deprivation, and morning restorative sleep. The measured immunoreactivity decreased during the transition from wakefulness to sleep at various times of the day and was not associated with a specific sleep phase [18]. This is scientifically interesting because it does not fit the simple assumption that circulating DSIP levels increase to induce delta sleep. However, the test measured immunoreactive material rather than intact, biologically active DSIP, and the study did not involve the administration of DSIP or an assessment of its effect on recovery following sleep deprivation.

There are no reliable human studies showing that DSIP prevents the cognitive, emotional, metabolic, immunological, or safety-related consequences of insufficient sleep. Therefore, it should not be presented as a substitute for adequate sleep, a countermeasure to shift work fatigue, or a way to „make up” for sleep debt. Such uses remain unproven.

Can DSIP cause worsening sleep, lack of sleep, or insomnia?

In theory, DSIP may impair sleep in certain situations; however, the available studies are far too limited to estimate the prevalence of paradoxical or adverse sleep-related reactions.

Several observations argue against the assumption that DSIP always promotes sleep. In a study involving six individuals with insomnia, mild arousal was observed in the first hour after administration, prior to a subsequent improvement in sleep parameters [5]. In cats, intraperitoneal administration of DSIP decreased light slow-wave sleep and REM sleep, and prolonged the latency to REM onset [14]. In an anesthetic study involving 24 women, DSIP altered EEG indices related to the depth of anesthesia as well as autonomic parameters, with some observations interpreted as a possible lightening rather than deepening of anesthesia [19]. These results stem from very different settings and do not allow for predicting individual responses, but they demonstrate that DSIP does not act as a simple biological sleep switch.

The available literature does not allow for the determination of the prevalence of insomnia, vivid dreams, nightmares, daytime sleepiness, spillover in the form of increased wakefulness, or changes in REM sleep. The studies were too small and, for the most part, too old to establish a contemporary database of adverse effects. An additional source of uncertainty is the quality of unapproved products sold as research peptides: the label alone does not confirm their identity, purity, sterility, concentration, or stability during storage.

Persistent insomnia, excessive daytime sleepiness, loud snoring or episodes of choking, unusual movements during sleep, or sleep deprivation combined with significant mood changes require clinical evaluation. These symptoms may occur in sleep apnea, circadian rhythm disorders, restless legs syndrome, medication side effects, psychoactive substance use, depression, anxiety, mania, pain, and other conditions that the peptide experiment cannot diagnose.

DSIP and melatonin

Melatonin has a specific circadian mechanism and a significantly larger base of human studies, whereas for DSIP no specific receptor has been confirmed and there is only a small number of inconsistent studies regarding insomnia.

Melatonin is a hormone produced mainly at night under the control of the circadian rhythm system. It acts through the identified MT1 and MT2 receptors and serves as a biological signal of darkness that can shift or enhance the timing of sleep. Its effectiveness depends heavily on the time of administration, the population, the formulation, and the specific sleep problem; it is not a universal sedative. A meta-analysis of 19 randomized, placebo-controlled trials involving 1,683 participants showed a statistically significant but, on average, modest improvement in time to sleep onset, total sleep time, and sleep quality [20]. Although this body of evidence also has limitations, it is significantly larger and more consistent than the literature on DSIP.

In the case of DSIP, however, no specific receptor or established role in the human circadian system has been confirmed [2,3]. Human studies have used experimental intravenous administration and have not shown consistent improvements in sleep or perceived sleep quality [4–11]. Comparing the two compounds solely by their names—„sleep hormone” and „sleep-inducing peptide”—therefore overlooks a fundamental difference in the level of evidence.

One should not assume that any of these compounds is suitable for every type of sleep problem. Circadian rhythm disorders differ from psychophysiological insomnia, sleep apnea, medication-induced insomnia, or simply insufficient time allocated for sleep. Regulations regarding melatonin and product quality also vary by country. The lack of efficacy of melatonin is not a basis for using unapproved DSIP, and the literature does not establish a validated dose conversion factor, method of combination, or strategy for direct comparison of the two compounds. Furthermore, no clinical trial comparing DSIP with melatonin has been conducted to demonstrate the superiority of one over the other.

DSIP compared to other sleep peptides and sleeping aids

DSIP remains an experimental peptide, whereas established treatments for insomnia typically have specific therapeutic goals, larger controlled clinical trials, and better-documented safety profiles.

The term „sleep peptide” can refer to biologically very different molecules. Orexin, also called hypocretin, is an endogenous neuropeptide system that promotes wakefulness. Approved orexin receptor antagonists are small molecules that block orexin signaling; they are neither DSIP nor peptide supplements. Other experimental DSIP analogues may also behave differently than the native molecule. For example, a 2024 mouse study tested a modified DSIP fusion construct designed to improve brain delivery in a chemically induced insomnia model. This fusion peptide is not equivalent to native DSIP, and behavioral or neurotransmitter results in mice do not constitute evidence of efficacy in human insomnia [21].

Sleep medications that act through the GABA system—including benzodiazepines and so-called “Z-drugs”—enhance signaling at specific GABA-A receptor complexes and may facilitate sleep, although, depending on the specific drug and patient, they are associated with recognized risks such as impaired performance the following day, falls, tolerance, dependence, and complex behaviors during sleep. In an ex vivo experiment on rat neurons, DSIP enhanced GABA-activated currents and influenced NMDA/glutamate signaling [22]. However, this mechanistic observation does not make DSIP equivalent to a GABA-acting hypnotic, as the study did not involve humans and did not confirm a therapeutic receptor, clinically relevant exposure, or a margin of safety.

CBT-I is not a medication, but it is relevant to this comparison because it addresses the behaviors and cognitive processes that underlie chronic insomnia. It typically involves stimulus control, structured sleep scheduling, cognitive techniques, and modification of behaviors that interfere with sleep. Comparing DSIP exclusively with pharmacological agents may mistakenly suggest that chronic insomnia always requires a biological „sleep-inducing” substance.

This comparison does not identify a single, universal „winner.” The appropriate course of action depends on the diagnosis, age, health status, other medications, pregnancy, risk of respiratory disorders, work schedule, and the balance between nighttime benefits and daytime impairment. However, it does demonstrate why DSIP cannot currently be placed on the same level of evidence as established treatments for insomnia.

Limitations of Evidence Regarding Sleep

Literature on DSIP and sleep is limited by very small study groups, older research methods, inconsistent results, uncertainty regarding the measurement of the molecule itself, and a lack of contemporary confirmatory studies.

Most human studies included only six to eighteen participants. Such small sample sizes are susceptible to random baseline differences, seemingly large treatment effects, and selective results when analyzing multiple EEG variables and sleep stages. Several positive publications also came from affiliated researchers and may have represented related or partially overlapping projects rather than fully independent replications. Some studies were open-label or lacked an adequate placebo group, making participants’ expectations and the natural variability of insomnia particularly important confounding factors.

The routes of administration and formulations used in historical studies also limit their applicability in real-world conditions. In human experiments, DSIP was typically administered slowly intravenously under the supervision of researchers. These studies do not support oral, subcutaneous, intranasal, or other modern commercial formulations, nor do they demonstrate that the amount listed on the retail vial label is safe or effective. Pharmacokinetic data are insufficient to assume comparable brain exposure across different routes of administration.

The biological mechanism of action itself also remains unexplained. No specific DSIP receptor has been confirmed, and immunoassays may detect DSIP-like material instead of the intact peptide [2,3,18]. Animal study results additionally vary depending on the species, time of administration, route of administration, and form of the molecule. Native DSIP, phosphorylated DSIP, truncated analogues, related KND peptides, and modified fusion constructs intended for brain delivery should therefore be treated as distinct experimental interventions.

Finally, available data lack many elements expected in modern insomnia therapy development: adequately sized randomized trials, prospectively registered protocols, reproducible dose-response relationships, validated patient-reported symptom severity indices, systematic adverse event assessment, daytime functioning outcomes, comparisons with established treatments, and longer follow-up. The lack of evidence does not mean that DSIP has no biological activity, but it constitutes a strong argument against presenting its potential sleep benefits as confirmed clinical effects.

FAQ: DSIP for Sleep

Is DSIP a sleeping pill?

No. Delta sleep-inducing peptide is an experimental nonapeptide, not an approved sleep medication. Small historical studies tested controlled intravenous administration, yielding inconsistent results. DSIP has no confirmed receptor, established clinical dosage standard for insomnia, or contemporary efficacy and safety research program comparable to an approved sleep medication.

Does DSIP increase deep sleep?

Some animal studies have shown an increase in deep slow-wave sleep or delta activity in the EEG, but the effect was inconsistent depending on the route of administration and the experiment. Studies in humans with insomnia have not shown a reliable increase in slow-wave sleep; in one controlled study, the increase in NREM sleep resulted mainly from the prolongation of stage 2, while stages 3 and 4 remained unchanged [10]. Therefore, it is not correct to claim that DSIP reliably increases the N3 stage in humans.

Does DSIP increase REM sleep?

Results for native DSIP are mixed. One very small human study showed a slight increase in REM sleep, whereas a controlled study in insomnia showed no significant change in REM [5,10]. Some studies of phosphorylated DSIP in rats showed an increase in paradoxical/REM sleep, while another study of native DSIP in cats showed a decrease [14–16]. Differences in molecules, species, and routes of administration make it impossible to predict the REM effect in humans.

How quickly does DSIP work on sleep?

There is no clinically established time of onset. Early human studies described delayed effects, sometimes preceded by a period of mild stimulation, but these observations come from very small studies involving intravenous administration [4–6]. They cannot be reliably applied to commercial products, other routes of administration, or retail vial strengths.

Is DSIP a proven remedy for chronic insomnia?

No. Several small studies have shown favorable changes in sleep parameters, but other double-blind studies have shown little clinical significance or no improvement in subjective sleep quality [10,11]. No large modern studies have been conducted to confirm a lasting improvement in insomnia severity or daytime functioning.

Can DSIP replace sleep after deprivation?

There is no evidence that DSIP can replace lost sleep. In an experiment on cats following sleep deprivation, a redistribution toward deeper slow-wave sleep was observed without an increase in total sleep time or restoration of lost REM sleep [17]. A small human sleep deprivation study was observational in nature and did not test DSIP treatment [18]. DSIP should not be presented as a protection against the health or safety consequences of insufficient sleep.

Is DSIP better than melatonin?

No direct human studies have been conducted to demonstrate the superiority of DSIP over melatonin. Melatonin acts via identified receptors and has a much larger base of randomized studies, although its average benefits are usually small and depend on the indication and timing of administration [20]. The mechanism and clinical utility of DSIP remain uncertain.

What does „DSIP 5 mg” mean?

Usually, this means the seller is declaring the presence of 5 milligrams of material in the vial. This does not mean that 5 mg is a clinically tested dose, that the product's contents have been independently verified, or that regulatory agencies have approved it for sleep use. The FDA substance base recognizes emideltide/DSIP as a chemical identity, but notes that the assignment of a substance identifier does not imply regulatory evaluation or approval [23].

Is DSIP approved by the FDA or EMA for the treatment of insomnia?

No. DSIP, or emideltide, is not an FDA- or EMA-approved treatment for insomnia. The presence of a substance in a regulatory database is not equivalent to a marketing authorization. Since regulatory status can change, current information should be checked in official FDA and EMA drug databases rather than in vendor descriptions.

What to do in case of persistent sleep problems?

Persistent insomnia should be evaluated in the context of its cause rather than treated as a presumed „peptide deficiency.” A licensed healthcare provider can assess the amount of time devoted to sleep, circadian rhythm, medications and substances used, mental and physical health, sleep apnea, restless legs syndrome, and other potential causes, and then discuss evidence-based treatment methods. Urgent evaluation is especially important when sleep deprivation is accompanied by dangerous daytime sleepiness, pauses in breathing, mania, suicidal ideation, or other acute symptoms.

Disclaimer

This content is for educational and scientific-informational purposes only and should not be interpreted as medical advice, diagnosis, treatment recommendation, dosage information, or a recommendation for the use of DSIP. The article should not be used for self-treatment of sleep disorders or for making decisions regarding the purchase, preparation, reconstitution, or self-administration of an unapproved peptide. Delta sleep-inducing peptide (DSIP/emideltide) is an experimental peptide and has not been approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of insomnia, sleep deprivation, improving sleep quality, or any other sleep-related indication discussed in this article. Available human study data are limited, largely date back several decades, and are inconsistent, while a significant portion of the additional literature involves animal studies, ex vivo experiments, or mechanistic observations.

References

1. Schoenenberger, G. A., & Monnier, M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the United States of America, 74(3), 1282–1286. https://doi.org/10.1073/pnas.74.3.1282
2. Graf, M. V., & Kastin, A. J. (1986). Delta-sleep-inducing peptide (DSIP): An update. Peptides, 7(6), 1165–1187. https://doi.org/10.1016/0196-9781(86)90148-8
3. Kovalzon, V. M., & Strekalova, T. V. (2006). Delta sleep-inducing peptide (DSIP): A still unresolved riddle. Journal of Neurochemistry, 97(2), 303–309. https://doi.org/10.1111/j.1471-4159.2006.03693.x
4. Schneider-Helmert, D., Gnirss, F., Monnier, M., Schenker, J., & Schoenenberger, G. A. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 19(8), 341–345. https://pubmed.ncbi.nlm.nih.gov/6895513/
5. Schneider-Helmert, D., & Schoenenberger, G. A. (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia, 37(9), 913–917. https://doi.org/10.1007/BF01971753
6. Schneider-Helmert, D., & Schoenenberger, G. A. (1983). Effects of DSIP in man: Multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology, 9(4), 197–206. https://doi.org/10.1159/000117964
7. Kaeser, H. E. (1984). A clinical trial with DSIP. European Neurology, 23(5), 386–388. https://doi.org/10.1159/000115717
8. Schneider-Helmert, D. (1986). Efficacy of delta-sleep-inducing peptide to normalize sleep in middle-aged and elderly chronic insomniacs. European Neurology, 25(6), 448–453. https://doi.org/10.1159/000116050
9. Schneider-Helmert, D. (1987). Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behavior in severe chronic insomnia. European Neurology, 27(2), 120–129. https://doi.org/10.1159/000116143
10. Monti, J. M., Debellis, J., Alterwain, P., Pellejero, T., & Monti, D. (1987). Study of the efficacy of delta sleep-inducing peptide in the treatment of insomnia. International Journal of Clinical Pharmacology Research, 7(2), 105–110. https://pubmed.ncbi.nlm.nih.gov/3583493/
11. Bes, F., Hofman, W., Schuur, J., & Van Boxtel, C. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 26(4), 193–197. https://doi.org/10.1159/000118919
12. Susić, V., Masirević, G., & Totić, S. (1987). Effects of delta sleep-inducing peptide on wakefulness and sleep patterns in the cat. Brain Research, 414(2), 262–270. https://doi.org/10.1016/0006-8993(87)90006-0
13. Susić, V. (1987). Effects of subcutaneous administration of delta sleep-inducing peptide on the sleep-waking cycle in the cat. Physiology & Behavior, 40(5), 569–572. https://doi.org/10.1016/0031-9384(87)90098-9
14. Sommerfelt, L. (1985). Reduced sleep in cats after intraperitoneal injection of delta sleep-inducing peptide. Neuroscience Letters, 58(1), 73-77. https://doi.org/10.1016/0304-3940(85)90331-3
15. Nakagaki, K., Ebihara, S., Usui, S., Honda, Y., & Takahashi, Y. (1988). Sleep-promoting effect of delta sleep-inducing peptide (DSIP) following the intracerebroventricular injection of its phosphorylated analogue in the rat. Neuroscience Letters, 91(2), 160–164. https://doi.org/10.1016/0304-3940(88)90761-6
16. Kimura, M., & Inoué, S. (1989). The phosphorylated analogue of DSIP enhances slow wave sleep and paradoxical sleep in unrestrained rats. Psychopharmacology, 97(1), 35–39. https://doi.org/10.1007/BF00443409
17. Susić, V., & Masirević, G. (1985). Effects of delta sleep-inducing peptide on the sleep cycle of cats deprived of paradoxical sleep. Archives Internationales de Physiologie et de Biochimie, 93(4), 271–277. https://doi.org/10.3109/13813458509079606
18. Seifritz, E., Müller, M. J., Schönenberger, G. A., Trachsel, L., Hemmeter, U., Hatzinger, M., Ernst, A., Moore, P., & Holsboer-Trachsler, E. (1995). Human plasma DSIP decreases at the initiation of sleep at different circadian times. Peptides, 16(8), 1475–1481. https://doi.org/10.1016/0196-9781(95)02027-6
19. Pomfrett, C. J. D., Dolling, S., Anders, N. R. K., Glover, D. G., Bryan, A., & Pollard, B. J. (2009). Delta sleep-inducing peptide alters bispectral index, electroencephalographic power spectrum, and heart rate variability during isoflurane anaesthesia. European Journal of Anaesthesiology, 26(2), 128–134. https://doi.org/10.1097/EJA.0b013e32831c8644
20. Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013). Meta-analysis: Melatonin for the treatment of primary sleep disorders. PLOS ONE, 8(5), e63773. https://doi.org/10.1371/journal.pone.0063773
21. Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA insomnia mouse models. Frontiers in Pharmacology, 15, 1439536. https://doi.org/10.3389/fphar.2024.1439536
22. Grigor’ev, V. V., Ivanova, T. A., Kustova, E. A., Petrova, L. N., Serkova, T. P., & Bachurin, S. O. (2006). Effects of delta sleep-inducing peptide on pre- and postsynaptic glutamate and postsynaptic GABA receptors in neurons of the cortex, hippocampus, and cerebellum in rats. Bulletin of Experimental Biology and Medicine, 142(2), 186–188. https://doi.org/10.1007/s10517-006-0323-9
23. U.S. Food and Drug Administration. (n.d.). Emideltide: UNII YN28Z5YZ73. Global Substance Registration System. https://precision.fda.gov/uniisearch/srs/unii/yn28z5yz73